Radiation Pneumonitis Risk Factors in NSCLC Patients Identified

Strategic Insights -

Researchers at the General Hospital of Ningxia Medical University have identified significant risk factors for radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients treated with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and thoracic radiotherapy (TRT). The study found that the incidence of RP was significantly higher in patients who received a third-generation EGFR TKI in combination with TRT, and that the risk of RP could be reduced by adjusting lung radiation dosimetry parameters.

Key Takeaways:

  • The study retrospectively evaluated 42 NSCLC patients who received both third-generation EGFR TKIs and TRT at the General Hospital of Ningxia Medical University from January 2023 to September 2024.
  • Of the 42 patients included, 26 (61.9%) developed RP, and 14 (33.3%) developed grade 2 RP.
  • The median time from TRT to RP was 3.69 months (2-10 months).
  • GTV 39 ml and total lung V20 14.95% were found to be independent risk factors for RP development.
  • The risk of RP in these patients can be reduced by adjusting lung radiation dosimetry parameters.
  • The timing and dose of TRT addition must be strictly controlled to optimize the therapeutic strategy and reduce the incidence of RP.

Statistics:

  • 61.9% of patients developed RP.
  • 33.3% of patients developed grade 2 RP.
  • The median time from TRT to RP was 3.69 months (2-10 months).
  • GTV 39 ml was an independent risk factor for RP development.
  • Total lung V20 14.95% was an independent risk factor for RP development.

Sources:

  • Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy. Radiation Oncology, 2025,20(1):1-10. (Radiation Oncology - http://www.ro-journal.com/).
  • Reports from General Hospital of Ningxia Medical University Highlight Recent Research in Radiation Pneumonitis (Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy). Respiratory Therapeutics Week. May 26, 2025; p 1315.